HAB Pharmaceuticals & Research Limited has unveiled an ambitious growth strategy after successfully completing its merger with Signature Phytochemical Industries.

The move has created a stronger and more integrated pharmaceutical organization with an estimated turnover of approximately Rs. 600 crore.

The merger, completed in March 2026 through a slump sale transaction, brings both businesses under a single corporate structure aimed at improving operational efficiency, strengthening governance, and creating a scalable platform for future growth.

The company has set an aggressive target of achieving revenues between Rs. 2,500 crore and Rs. 3,000 crore by 2030.

The combined entity plans to leverage enhanced manufacturing infrastructure, expanded research and development capabilities, and a growing portfolio of specialty pharmaceutical products to drive long-term growth.

The merger significantly expands HAB Pharmaceuticals' manufacturing and R&D ecosystem, enabling the company to focus on off-patent molecules and complex dosage forms across several high-growth therapeutic areas. Key focus segments include oncology, autoimmune disorders, chronic diseases, and rare disease treatments, where demand for specialized therapies continues to increase globally.

As part of its growth roadmap, HAB Pharmaceuticals is investing in advanced manufacturing infrastructure with two new facilities expected to begin commercial production by August 2026.

One of the facilities is a sterile manufacturing plant designed to produce semaglutide products, prefilled syringes, injectables, vials, and lyophilized formulations. The second facility is a fully automated closed-loop Oral Solid Dosage (OSD) manufacturing unit aimed at improving production efficiency, ensuring consistent quality, and supporting higher volumes.